A Phase 3 interventional study of Doxorubicin hydrochloride (liposomal) in Sarcoma, Kaposi and HIV Infections, sponsored by Sequus Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Sequus Pharmaceuticals · Phase 3, Interventional, and Treatment
To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with Kaposi's sarcoma who have previously received systemic chemotherapy with or without an anthracycline.
Patients receive DOX-SL every 3 weeks for up to 20 cycles.
162 studies on the registry are indexed under Sarcoma, Kaposi; 29 are open to participants now.
Browse Sarcoma, Kaposi studies →Sequus Pharmaceuticals is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients must have:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Patients with the following prior condition are excluded:
History of idiosyncratic or allergic reaction to anthracyclines.
Prior Medication:
Excluded:
This study is completed, as verified in Jan 1996. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sequus Pharmaceuticals